PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954609
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954609
Human Antithrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of human antithrombin Market
The global human antithrombin market was valued at USD 381.32 million in 2025 and is projected to grow from USD 396.34 million in 2026 to USD 566.36 million by 2034, registering a CAGR of 4.56% during the forecast period (2026-2034). In 2025, Europe dominated the market with a 43.17% share, supported by strong plasma fractionation infrastructure and the presence of leading manufacturers.
Human antithrombin is a plasma-derived glycoprotein that plays a vital role in regulating blood coagulation by inactivating thrombin and other serine proteases. It is widely used for preventing abnormal blood clotting, particularly in patients with hereditary antithrombin deficiency and in high-risk surgical or critical care settings.
Market Overview
Human antithrombin concentrates are essential in managing coagulation disorders, especially in patients undergoing complex surgical procedures or those suffering from thrombophilia and disseminated intravascular coagulation (DIC). The growing prevalence of cardiovascular diseases, increasing organ transplant procedures, and rising use of extracorporeal membrane oxygenation (ECMO) are key factors contributing to market expansion.
Major companies operating in this market include CSL, Octapharma AG, Grifols, S.A., Kedrion S.p.A., and Takeda Pharmaceutical Company Limited. Their strong presence in plasma-derived medicinal products strengthens overall market growth.
Market Dynamics
Market Drivers
Increasing Usage for Therapeutic Applications
The primary growth driver is the expanding therapeutic application of human antithrombin. The rising number of cardiac surgeries, organ transplants, and critically ill patients requiring anticoagulant therapy is increasing demand. According to a June 2024 article published in Annals of Thoracic Surgery Short Reports, the annual average cardiac surgery volume in the U.S. reached 271.5 procedures per 100,000 population.
Hereditary antithrombin deficiency affects approximately 0.02% to 0.05% of the global population, creating sustained demand for lifelong supplementation therapy. Surgeons and ICU physicians increasingly depend on fast-acting antithrombin formulations, supporting market growth from USD 396.34 million in 2026 to USD 566.36 million by 2034.
Market Restraints
Safety Concerns and Side Effects
Despite widespread therapeutic use, plasma-derived antithrombin concentrates carry certain risks. These include allergic reactions, anaphylaxis, bleeding complications, and thromboembolic events. There is also a minimal risk of transmission of unknown infectious agents, despite rigorous safety measures. In cases of severe sepsis, high-dose antithrombin III combined with heparin may increase hemorrhage risk. These factors limit adoption in certain clinical scenarios.
Market Opportunities
Expansion into Combination Therapies
Growing research on combination therapies is creating new opportunities. Studies indicate that combining antithrombin with heparin produces synergistic anticoagulant effects. Healthcare professionals are increasingly exploring such combinations to enhance therapeutic outcomes. The expansion of applications beyond hereditary deficiency, particularly in sepsis and DIC management, is expected to provide long-term growth opportunities.
Market Challenges
Complex Regulatory and Reimbursement Frameworks
Strict regulatory requirements for plasma-derived products slow product approvals and commercialization timelines. Additionally, reimbursement disparities across countries limit accessibility, especially in low- and middle-income nations. These challenges can restrain market penetration despite clinical demand.
Market Trends
Expanding Clinical Applications
Antithrombin is increasingly used beyond hereditary deficiency treatment. In Japan, anticoagulation therapy for septic patients with DIC includes antithrombin concentrate as part of standard care. A dose of 1,500 IU/day has been approved within the Japanese healthcare system. Such expanded clinical applications represent a notable market trend.
Segmentation Analysis
By Application
The market is segmented into therapeutic and research & diagnostic applications.
- The therapeutic segment dominated the market in 2024 and continues to lead due to high clinical demand. Antithrombin supplementation is widely used to manage heparin resistance. In December 2024, the American Society of Hematology highlighted antithrombin supplementation as a preferred treatment in such cases.
- The research & diagnostic segment holds a smaller share due to limited product availability.
By Dosage Form
The market is categorized into lyophilized powder and liquid formulations.
- Lyophilized powder held the dominant share in 2024, owing to enhanced stability and ease of storage. Products such as THROMBATE III (Grifols) and Thrombotrol VF (CSL) are available in this form.
- The liquid segment accounts for a smaller share due to limited commercial availability.
By End User
The market includes hospitals & clinics, pharmaceutical & biotechnology companies, and research institutes.
- Hospitals & clinics held the largest share in 2024 due to increased usage in surgical and critical care settings.
- The pharmaceutical and biotechnology segment is expected to grow steadily due to expanding research applications.
Regional Outlook
Europe
Europe led the market with a value of USD 164.62 million in 2025 and a 43.17% market share. Growth is driven by strong plasma manufacturing infrastructure, supportive government initiatives such as "France 2030," and the presence of major players like LFB and Grifols.
Asia Pacific
Asia Pacific is projected to witness the fastest growth due to rising congenital deficiency cases and strategic collaborations. For example, in 2019, SK Pharma partnered with BioPharma Indonesia for plasma production initiatives.
North America
North America holds a comparatively smaller share due to regulatory hurdles limiting product approvals.
Rest of the World
Latin America and the Middle East & Africa are experiencing gradual growth, supported by improving healthcare access.
Competitive Landscape
The market is semi-consolidated, with leading players including CSL, Grifols, Kedrion, and Octapharma AG. These companies maintain strong global distribution networks and plasma-derived product portfolios. Strategic collaborations, facility expansions, and clinical trials are shaping the competitive environment.
Conclusion
The global human antithrombin market is expected to grow steadily from USD 381.32 million in 2025 to USD 566.36 million by 2034, driven by rising surgical procedures, increasing cases of hereditary deficiency, and expanding therapeutic applications. While safety concerns and regulatory complexities present challenges, ongoing research, combination therapies, and strong European leadership are likely to sustain long-term market expansion. As healthcare systems continue to prioritize advanced anticoagulation management, human antithrombin will remain a critical component in treating complex coagulation disorders worldwide.
Segmentation By Application
- Therapeutic
- Research & Diagnostic
By Dosage Form
- Lyophilized Powder
- Liquid
By End User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Industry
- Research Institutes
By Region
- North America (By Application, Dosage Form, End User, and Country/Sub-Region)
- U.S.
- Canada
- Europe (By Application, Dosage Form, End User, and Country/Sub-Region)
- Germany
- France
- U.K.
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Application, Dosage Form, End User, and Country/Sub-Region)
- China
- India
- Japan
- Australia
- South Korea
- Southeast Asia
- Rest of the Asia Pacific
- Rest of the World (By Application, Dosage Form, and End User)
Table of Content
1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Cardiovascolar Diseases, By Key Countries
- 4.2. Regolatory Scenario, By Key Countries
- 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)
5. Global Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Application
- 5.1.1. Therapeutic
- 5.1.2. Research & Diagnostic
- 5.2. Market Analysis, Insights and Forecast - By Dosage Form
- 5.2.1. Lyophilized Powder
- 5.2.2. Liquid
- 5.3. Market Analysis, Insights and Forecast - By End User
- 5.3.1. Hospitals & Clinics
- 5.3.2. Pharmaceutical & Biotechnology Industry
- 5.3.3. Research Institutes
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
6. North America Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Application
- 6.1.1. Therapeutic
- 6.1.2. Research & Diagnostic
- 6.2. Market Analysis, Insights and Forecast - By Dosage Form
- 6.2.1. Lyophilized Powder
- 6.2.2. Liquid
- 6.3. Market Analysis, Insights and Forecast - By End User
- 6.3.1. Hospitals & Clinics
- 6.3.2. Pharmaceutical & Biotechnology Industry
- 6.3.3. Research Institutes
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Application
- 7.1.1. Therapeutic
- 7.1.2. Research & Diagnostic
- 7.2. Market Analysis, Insights and Forecast - By Dosage Form
- 7.2.1. Lyophilized Powder
- 7.2.2. Liquid
- 7.3. Market Analysis, Insights and Forecast - By End User
- 7.3.1. Hospitals & Clinics
- 7.3.2. Pharmaceutical & Biotechnology Industry
- 7.3.3. Research Institutes
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. Germany
- 7.4.2. UK
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Application
- 8.1.1. Therapeutic
- 8.1.2. Research & Diagnostic
- 8.2. Market Analysis, Insights and Forecast - By Dosage Form
- 8.2.1. Lyophilized Powder
- 8.2.2. Liquid
- 8.3. Market Analysis, Insights and Forecast - By End User
- 8.3.1. Hospitals & Clinics
- 8.3.2. Pharmaceutical & Biotechnology Industry
- 8.3.3. Research Institutes
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. South Korea
- 8.4.6. Southeast Asia
- 8.4.7. Rest of Asia Pacific
9. Rest of World Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Application
- 9.1.1. Therapeutic
- 9.1.2. Research & Diagnostic
- 9.2. Market Analysis, Insights and Forecast - By Dosage Form
- 9.2.1. Lyophilized Powder
- 9.2.2. Liquid
- 9.3. Market Analysis, Insights and Forecast - By End User
- 9.3.1. Hospitals & Clinics
- 9.3.2. Pharmaceutical & Biotechnology Industry
- 9.3.3. Research Institutes
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. CSL
- 10.2.1.1. Overview
- 10.2.1.2. Products
- 10.2.1.3. Financials (Based on Availability)
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. SWOT,Etc.
- 10.2.2. Octapharma AG
- 10.2.2.1. Overview
- 10.2.2.2. Products
- 10.2.2.3. Financials (Based on Availability)
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. SWOT,Etc.
- 10.2.3. Takeda Pharmaceutical Company Limited
- 10.2.3.1. Overview
- 10.2.3.2. Products
- 10.2.3.3. Financials (Based on Availability)
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. SWOT,Etc.
- 10.2.4. Grifols, S.A.
- 10.2.4.1. Overview
- 10.2.4.2. Products
- 10.2.4.3. Financials (Based on Availability)
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. SWOT,Etc.
- 10.2.5. Medix Biochemica
- 10.2.5.1. Overview
- 10.2.5.2. Products
- 10.2.5.3. Financials (Based on Availability)
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. SWOT,Etc.
- 10.2.6. Kedrion S.p.A.
- 10.2.6.1. Overview
- 10.2.6.2. Products
- 10.2.6.3. Financials (Based on Availability)
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. SWOT,Etc.
- 10.2.7. Scripps Laboratories
- 10.2.7.1. Overview
- 10.2.7.2. Products
- 10.2.7.3. Financials (Based on Availability)
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. SWOT,Etc.
- 10.2.1. CSL
List of Tables
- Table 1: Global Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
- Table 2: Global Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
- Table 3: Global Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
- Table 4: Global Human Antithrombin Market Revenue (USD million) Forecast, by Region, 2021-2034
- Table 5: North America Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
- Table 6: North America Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
- Table 7: North America Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
- Table 8: North America Human Antithrombin Market Revenue (USD million) Forecast, By Country, 2021-2034
- Table 9: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
- Table 10: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
- Table 11: Europe Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
- Table 12: Europe Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
- Table 14: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
- Table 15: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
- Table 16: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
- Table 18: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
- Table 19: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
List of Figures
- Figure 1: Global Human Antithrombin Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
- Figure 2: Global Human Antithrombin Market Value Share (%), by Application, 2025 & 2034
- Figure 3: Global Human Antithrombin Market Value Share (%), by Dosage Form, 2025 & 2034
- Figure 4: Global Human Antithrombin Market Value Share (%), by End User, 2025 & 2034
- Figure 5: Global Human Antithrombin Market Value (USD million), by Region, 2025 & 2034
- Figure 6: North America Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
- Figure 7: North America Human Antithrombin Market Value Share (%), by Application, 2025
- Figure 8: North America Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
- Figure 9: North America Human Antithrombin Market Value Share (%), by Dosage Form, 2025
- Figure 10: North America Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
- Figure 11: North America Human Antithrombin Market Value Share (%), by End User, 2025
- Figure 12: North America Human Antithrombin Market Value (USD million), By Country, 2025 & 2034
- Figure 13: North America Human Antithrombin Market Value Share (%), By Country, 2025
- Figure 14: Europe Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
- Figure 15: Europe Human Antithrombin Market Value Share (%), by Application, 2025
- Figure 16: Europe Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
- Figure 17: Europe Human Antithrombin Market Value Share (%), by Dosage Form, 2025
- Figure 18: Europe Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
- Figure 20: Europe Human Antithrombin Market Value Share (%), by End User, 2025
- Figure 21: Europe Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
- Figure 22: Europe Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 23: Asia Pacific Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
- Figure 24: Asia Pacific Human Antithrombin Market Value Share (%), by Application, 2025
- Figure 25: Asia Pacific Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
- Figure 26: Asia Pacific Human Antithrombin Market Value Share (%), by Dosage Form, 2025
- Figure 27: Asia Pacific Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
- Figure 28: Asia Pacific Human Antithrombin Market Value Share (%), by End User, 2025
- Figure 29: Asia Pacific Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
- Figure 30: Asia Pacific Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 31: Rest of the World Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
- Figure 32: Rest of the World Human Antithrombin Market Value Share (%), by Application, 2025
- Figure 33: Rest of the World Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
- Figure 34: Rest of the World Human Antithrombin Market Value Share (%), by Dosage Form, 2025
- Figure 35: Rest of the World Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
- Figure 36: Rest of the World Human Antithrombin Market Value Share (%), by End User, 2025
- Figure 37: Global Human Antithrombin Market Share (%), By Company, 2025
